Indian Pharma likely to grow further!

Nourished by increasing spending, improving accessibility and growing exports, India's Pharma sector is ready for another year of robust growth which is likely to remain 12%-13% despite the covid challenges.

According to Experts improved access to medicines in India and exploring new markets while maintaining thrust in the US will help the country's Pharma industry to record double-digit growth in the coming year.

Despite the COVID-19 impact, the domestic Pharma industry may grow between 4%-6% in FY21 and may have 8%-11% compounded annual growth rate (CAGR) in the FY 2020-2023 period, mainly led by growth in the domestic market, predicts a ICRA research analysis.

The COVID-19 had minimal impact on the Indian pharmaceutical industry, which posted a stable growth of 8% during FY20 thanks to a domestic overall growth of 12.7% due to seasonal factors and stable growth in chronic therapies and a rebound of 14.2% growth in the second quarter of that year. ICRA's study of 21 leading companies said sample companies registered a domestic growth of 9.2% in second quarter and 4.8% growth in the first quarter of last financial year. The second quarter of last year had witnessed outbreak of many diseases in many parts, aiding the growth of the anti-infective segment.

"The credit metrics of leading Pharma companies are expected to remain stable in view of future growth prospects in regulated markets and relatively strong balance sheets” as said by experts.

Here we have some Pharma funds for you to invest in 2020:

*Data as on 27th November 2020.

To know more 

You can use GIIS Financial tools or Our Android App  for Investment, tracking and Asset allocation planning. 

Share On